The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof.
The present invention relates to a compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.
The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof.
The present invention relates to a compound represented by the formula
wherein each symbol is as defined in the present specification, or a salt thereof.
[EN] FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES FUSIONNÉS ET LEUR UTILISATION
申请人:TAKEDA PHARMACEUTICAL
公开号:WO2009136663A1
公开(公告)日:2009-11-12
The present invention provides a fused heterocyclic derivative having a strong kinase inhibitory activity and use thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.
Rhodium(III)‐Catalyzed C‐H/O
<sub>2</sub>
Dual Activation and Macrocyclization: Synthesis and Evaluation of Pyrido[2,1‐a]isoindole Grafted Macrocyclic Inhibitors for Influenza H1N1
Here is an unprecedented and practical RhIII-catalyzed acylmethylation macrocyclization via C−H/O2 dual activation. The reaction mode derives from a three-component coupling which differs from established olefination and alkylation paths. DFT calculations and control experiments revealed the mechanism of this unique C−H/O2 dual activation. The phenotypic screening result indicated that some macrocyclic